Wed, Aug 14, 8:16 PM (153 days ago)
On August 13, 2024, Windtree Therapeutics, Inc. reported significant leadership changes in its Board of Directors. Directors Daniel Geffken and Leslie J. Williams resigned, effective the same day, with no disagreements cited regarding company operations. In response, the Board appointed Jed Latkin and Saundra Pelletier to fill the vacancies. Latkin will chair the Audit Committee and serve on the Compensation Committee, while Pelletier will chair the Compensation Committee and participate in both the Nominating and Corporate Governance and Audit Committees. Both appointees are deemed independent under Nasdaq rules. Additionally, Mark Strobeck, Ph.D., was appointed as the lead independent director. These changes are expected to enhance the governance structure of the company, potentially impacting investor confidence and stock performance. The company’s compensation policies for directors and standard indemnification agreements will apply to the new appointees.